Physician profile
Mark A Thompson
NPI 1669444030
$9,319.16
in general payments reported to CMS, 2019-2025
41 companies · $1,337 in 2025
The $1,337 reported for 2025 was more than what 86% of Radiation Oncology providers received nationally (typical 2025 total: $172).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,198 · 2020: $1,025 · 2021: $1,472 · 2022: $1,554 · 2023: $1,566 · 2024: $1,166 · 2025: $1,337.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,069.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,069.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $1,129.21 | 2019-2025 | Xtandi |
| Dendreon Pharmaceuticals LLC | $914.21 | 2019-2023 | Provenge |
| Mevion_medical_systems_inc | $873.46 | 2020-2021 | |
| Novocure INC. | $723.73 | 2022-2025 | Optune Lua (Novottf-200t), Optune |
| Progenics Pharmaceuticals, INC. | $602.53 | 2022-2025 | Pylarify |
| Blue Earth Diagnostics | $577.05 | 2021-2025 | Posluma |
| Janssen Biotech, INC. | $519.98 | 2019-2024 | Erleada, Akeega |
| Teleflex LLC | $490.54 | 2022-2025 | Urolift, Barrigel |
| Bayer Healthcare Pharmaceuticals INC. | $487.69 | 2019-2024 | |
| Novartis Pharmaceuticals Corporation | $362.18 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $325.41 | 2019-2023 | Lynparza |
| Abbvie INC. | $283.14 | 2020-2024 | Lupron Depot |
| Sumitomo Pharma America, INC. | $217.65 | 2023-2025 | Orgovyx, Gemtesa |
| Boston Scientific Corporation | $197.57 | 2020-2024 | Spaceoar System |
| Myriad Genetic Laboratories, INC. | $176.24 | 2021-2025 | Prolaris, Myrisk |
Show all 41 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Rochester Medical Corporation | $155.13 | 2021-2022 | |
| Becton, Dickinson and Company | $127.12 | 2023-2024 | Bard Urinary Drainage Bag |
| Pfizer INC. | $113.87 | 2022-2025 | |
| Travere Therapeutics, INC. | $107.03 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $94.90 | 2022-2025 | Keytruda, Lynparza |
| Tolmar, INC. | $89.06 | 2023-2025 | Eligard, Jatenzo |
| 180 Medical, INC. | $72.99 | 2020-2022 | |
| Convatec INC. | $70.30 | 2019-2021 | |
| Tolmar Pharmaceuticals, INC. | $68.72 | 2022 | |
| Urogen Pharma, INC. | $67.12 | 2024-2025 | |
| Coloplast Corp | $60.65 | 2021-2023 | Isiris Astent Removal Device, Speedicath |
| Myovant Sciences INC. | $56.94 | 2022 | |
| C. R. Bard, INC. & Subsidiaries | $51.83 | 2023 | Bard Urinary Drainage Bag |
| Axonics, INC. | $41.76 | 2022-2024 | Bulkamid |
| Endo Pharmaceuticals INC. | $37.04 | 2019-2022 | |
| Olympus America INC. | $34.87 | 2019-2022 | |
| Immunitybio, INC. | $26.38 | 2025 | |
| Organogenesis INC. | $25.66 | 2023 | Puraply |
| Clarus Therapeutics INC. | $24.93 | 2021 | |
| Abc Home Medical Supply, INC. | $22.49 | 2025 | |
| Telix Pharmaceuticals | $18.70 | 2023 | Illuccix |
| Procept Biorobotics Corporation | $17.76 | 2024 | Aquabeam System |
| Kowa Pharmaceuticals America, INC. | $13.96 | 2022 | |
| Laborie Medical Technologies Corp. | $13.57 | 2024 | Optilume Bph Drug Coated Balloon Catheter |
| Urovant Sciences INC | $13.54 | 2022 | |
| Zyla Life Sciences, INC. | $12.25 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Thompson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.